CCT129957
CAS No. 883098-58-6
CCT129957( —— )
Catalog No. M33309 CAS No. 883098-58-6
CCT129957 is a novel and potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of about 3 μM and a GC50 of 15 μM.CCT129957 exhibits anticancer activity and inhibits Ca2+ release in squamous cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 59 | Get Quote |
|
| 5MG | 85 | Get Quote |
|
| 10MG | 128 | Get Quote |
|
| 25MG | 225 | Get Quote |
|
| 50MG | 338 | Get Quote |
|
| 100MG | 497 | Get Quote |
|
| 500MG | 1053 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCCT129957
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCT129957 is a novel and potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of about 3 μM and a GC50 of 15 μM.CCT129957 exhibits anticancer activity and inhibits Ca2+ release in squamous cells.
-
DescriptionCCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca2+ release in squamous carcinoma cells at ~15 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPhospholipase
-
RecptorPhospholipase | Calcium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number883098-58-6
-
Formula Weight309.32
-
Molecular FormulaC17H15N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (323.29 mM; Ultrasonic )
-
SMILES[O-][N+](=O)c1cccc2cc([nH]c12)C(=O)NCCc1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Reynisson J, et al. The identification of novel PLC-gamma inhibitors using virtual high throughput screening. Bioorg Med Chem. 2009 Apr 15;17(8):3169-76.?
molnova catalog
related products
-
Lp-PLA2-IN-1
Lp-PLA2 -IN-1 suppresses Lp-PLA2 activity processes for their preparation.
-
Linocinnamarin
Linocinnamarin is isolated from Fragaria ananassa Duch. (strawberry). The inhibition of antigen-stimulated degranulation by LN is mainly due to inactivation of Syk/phospholipase Cgamma (PLCgamma) pathways.
-
Atg4B-IN-2
Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs.
Cart
sales@molnova.com